Kazuyuki Numakura, Ryoma Igarashi, Makoto Takahashi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Takenori Niioka, Masatomo Miura, et al. Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma. Cancer biology & therapy. 2024. 25. 1. 2312602-2312602
Ryosuke Naka, Yoshimitsu Shimomura, Masatomo Miura, Yuya Nagai, Tadakazu Kondo, Takayuki Ishikawa. Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis. International journal of hematology. 2024
Hiroshi Ureshino, Naoto Takahashi, Takayuki Ikezoe, Yoshihiro Kameoka, Satoshi Kimura, Noriyasu Fukushima, Tatsuo Ichinohe, Ayako Takamori, Atsushi Kawaguchi, Masatomo Miura, et al. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial). International journal of hematology. 2024
Takahiro Kobayashi, Honami Sato, Masatomo Miura, Yayoi Fukushi, Wataru Kuroki, Fumiko Ito, Kazuaki Teshima, Atsushi Watanabe, Naohito Fujishima, Isuzu Kobayashi, et al. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia. Cancer chemotherapy and pharmacology. 2024. 94. 2. 285-296
Kazuma Fujita, Daiki Taguchi, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Hanae Shinozaki, Hiroyuki Shibata, Masatomo Miura. Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients. Investigational new drugs. 2024. 42. 3. 252-260